Introduction: Leadless pacemakers may provide a safe and attractive pacing option to patients with cardiac implantable electronic device (CIED) infection. We describe the characteristics and outcomes of patients with a recent CIED infection undergoing Micra implant attempt.
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Conclusion: Implantation of the Micra transcatheter pacemaker is safe and feasible in patients with a recent CIED infection. No recurrent infections that required Micra device removal were seen. Leadless pacemakers appear to be a safe pacing alternative for patients with CIED infection who undergo extraction. CIED infections are associated with a significant increase in hospital length of stay, cost, and mortality. [3] [4] [5] The average hospital length of stay for patients with pacemaker-related infections ranges from 15.5 to 24 days. 3 The cost associated with such admissions is significant, exceeding $28 000 in the U.S. and €23 000 in France. 4 More importantly, the 1-year mortality after pacemaker infections can exceed 35%. 3, 5 Furthermore, the risk of reinfection after reimplantation is around 2% and exceeds 11% in patients who had only partial removal of the original device. 6 Leadless pacemakers eliminate pocket-related infections and have the potential to reduce lead-related endocarditis. In the Micra leadless pacemaker investigational device exemption (IDE) study and post approval registry (PAR) no Micra device-related infections or any infections requiring device removal were observed. [7] [8] [9] Hence, Micra in the setting of device infection might be an appealing pacing alternative after CIED removal.
In this study we sought to determine the outcomes of patients enrolled in the Micra PAR with history of CIED infections that were implanted with a Micra pacemaker following prior system explant.
| METHODS
The design and rationale for of the Micra PAR study (ClinicalTrials. gov identifier: NCT02536118) have been reported previously. 9, 10 Briefly, the aim of the Micra PAR is to further evaluate short-and long-term safety and performance of the Micra transcatheter pacing system (TPS) when used in the "real-world" setting following commercial release. All patients intended to be implanted with a market-approved Micra device without restriction due to comorbidity or prior CIED status at participating centers were eligible for enrollment. Since the goal of this analysis was to analyze outcomes in clinical practice outside of an investigational clinical trial, patients that participated in the premarket trial to be complete if all previously implanted system components were recorded as being removed and partial if only a portion of the system components were recorded as being removed (eg, two of three components).
| Objective
The objective of the present analysis is to report on outcomes in patients receiving a Micra device following recent CIED infection.
Safety was assessed by summarizing major complications defined as events related to the Micra TPS or procedure resulting in death, permanent loss of device function, hospitalization, prolonged hospitalization by 48 hours or more, or system revision. Of particular interest for this analysis was the incidence of infection requiring device removal, thus reasons for any Micra system revision were also summarized. Medical history, implant characteristics, and electrical performance were also evaluated.
| Statistical methods
Patients with a history of CIED infection and/or reason for CIED explant reported as "infection" who had a full or partial CIED system explant within 30-days of their Micra implant attempt were identified. Summary statistics were obtained and reported using mean and standard deviation for continuous variables, and frequencies and percentages for categorical variables. The Kaplan-Meier method was used to estimate the all-cause mortality rate during follow-up. All analyses were conducted with SAS version 9.4 (SAS Institute, Cary, NC) or the R statistical package (R Project for Statistical Computing, Vienna, Austria).
| RESULTS
The Micra PAR database was frozen for analysis on 1 August 2018.
A total of 1820 patients were consented and underwent Micra implant as part of the Micra PAR registry of which 105 (5.8%) from 59 study centers had a prior CIED infection and underwent a Micra implant attempt within 30 days of their prior system explant. Table 1 summarizes the baseline characteristics of the cohort.
The mean age was 72.7 ± 14.7 years, 57.1% of patients had atrial tachyarrhythmias, 32% had diabetes, and 27.6% had renal dysfunction, of which 13 (45%) required dialysis. Investigators reported that 83 patients (79.0%) had a condition that precluded the use of transvenous pacing systems, of which 11 (13%) had stenosed/occluded subclavian veins and 4 (5%) had a need to preserve the subclavian vein (ie, dialysis). AF with bradycardia was the main indication for pacing in this cohort (49.5%) followed by atrioventricular block with intact sinus function (21.9%) ( Table 1 ). There were 33 patients (31.4%) considered to be pacemaker dependent (escape rhythm ≤30 bpm) by the implanting physician.
Prior CIED systems at the time of explant included single or dual chamber transvenous pacemakers (70.5%), cardiac resynchronization therapy pacemakers (CRT-P; 9.5%) and CRT-defibrillators (CRT-D) or defibrillators in 13 (12.4%) patients ( Table 1) . All infected CIED components present at baseline were explanted in 93.3% of patients, in the remaining 6.7%, only partial explant of components occurred. Six major complications occurred in four patients that were related to the Micra procedure or system (Table 3 ). These complications have been reported previously. 10 One patient developed an effusion requiring pericardiocentesis.
Another patient had three complications. After the release of Micra, a rise in threshold was noted and retrieval was attempted. During the retrieval the device became entangled in the patient's inferior vena There were no recurrent infections requiring Micra removal during the follow-up period.
A total of 10 deaths occurred during follow-up resulting in a mortality rate of 14.2% through 12-months after implant (Figure 1 ). 
| DISCUSSION
This is the largest study to date evaluating the outcomes of patients A small study of 17 patients that received a leadless pacemaker after extraction of an infected CIED system, showed no recurrent infection during a mean follow-up of 16 months. 12 Similarly, the use of Micra TPS after extraction of pre-existing pacing system in six patients with device infection proved safe without recurrence of any infection after 12 weeks of follow-up. 13 The data presented in this manuscript also show that Micra is a safe alternative in patients after extraction of infected CIED. No Micra infection was observed and no systemic infection that required device removal was encountered. This is an important finding especially in this patient population at high risk of recurrent infection. 6 Another notable observation is the low mortality rate Patients enrolled in this study had multiple comorbidities. Around 80% of these patients had a condition that precluded the use of a traditional transvenous device. This could explain why patients with pre-existing ICD or CRT devices (22% of our cohort) had Micra implant after CIED extraction (Table 1) . It is also possible that the indication for an ICD or CRT in these patients no longer existed at the time of CIED extraction.
The Micra pacemaker was implanted on average 6.5 days after device extraction, however 37.1% of patients had Micra implanted during the same procedure. Simultaneous reimplantation of a new pacing system after extraction of CIED for isolated pocket infection has been shown in single center studies to be feasible and not associated with increase in complications. 14 left to the discretion of the implanting physician. Patients were followed for a mean of 8.5 months; hence long-term infection recurrence might have been missed. In addition, no data were collected on the type and severity of the infection (ie, type of infection, presence or absence of bacteremia, and or endocarditis and type of antibiotics used). In addition, we cannot rule out that patients with less severe infection were more likely to be enrolled in this registry therefore introducing an important source of selection bias.
| STUDY LIMITATIONS
It is, however, the largest report on the outcomes of patients with history of CIED infection implanted with a leadless pacemaker.
| CONCLUSION
The Micra leadless pacemaker is a safe and feasible pacing option in patients with history of CIED infection. Its intracardiac location, small surface area, and tendency for encapsulation might provide an advantage in this patient population at risk of recurrent infections.
